Related content

Use of PEG-asparaginase in the treatment of patients with solid tumors

By Pinheiro João   Lanvers Claudia   Boos Joachim  

Cancer Chemotherapy and Pharmacology, Vol. 48, Iss. 5, 2001-11 ,pp. : 421-422

Springer Publishing Company

Access to resources Recommend Favorite

Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease. Implications for its use?

By Deneberg Stefan   Lerner Richard   Ljungman Per   Ringden Olle   Hägglund Hans  

Medical Oncology, Vol. 24, Iss. 3, 2007-09 ,pp. : 354-356

Humana Press, Inc

Access to resources Recommend Favorite

Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia - a report from the Children's Cancer Study Group

By von Stackelberg A.   Karatchunsky A.   Kudrjashova J.   Miakova N.   Belikova L.   Rumiantzev A.   Hartmann R.   Henze G.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1349-1355

Elsevier

Access to resources Recommend Favorite

l-Asparagine depletion levels and l-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment

By Tsurusawa Masahito   Chin Motoaki   Iwai Asayuki   Nomura Keiko   Maeba Hideaki   Taga Takashi   Higa Takeshi   Kuno Tomoko   Hori Toshinori   Muto Akiko   Yamagata Miyo  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 3, 2004-03 ,pp. : 204-208

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series

By Chamberlain Marc  

Journal of Neuro-Oncology, Vol. 113, Iss. 1, 2013-05 ,pp. : 27-32

Springer Publishing Company

Access to resources Recommend Favorite